Trump's 200% tariff plan may be a bitter pill for US consumers; Dr Reddy's warns of costlier medicines
The US plans to impose tariffs on imported generic medicines, rising to 200% after a phased schedule: 0% until August 1, 2028, then 100% for one year, followed by 200% thereafter.
Dr Reddy's Laboratories CEO Erez Israeli warned that higher tariffs will inevitably lead to increased medicine prices for US consumers.
Dr Reddy's stated that shifting manufacturing to the US is currently impractical due to the magnitude and cost difference between the US and other markets like Russia.
India is a major exporter of generic medicines to the US, making it significantly exposed to the tariff impact.
Story angle
Center-right
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Times of India
Center-right
Mixed factuality
Who owns this?
Times Group
Bennett, Coleman & Co. (Sahu Jain family)
India's largest newspaper group by circulation.
Wikipedia: Sahu Jain family